Rosenørn J, Eskesen V, Espersen J O, Haase J, Schmidt K
Department of Neurosurgery, Aalborg Hospital, Denmark.
Br J Neurosurg. 1988;2(4):447-53. doi: 10.3109/02688698809029598.
In a prospective consecutive non-randomised study including 1076 patients with ruptured intracranial aneurysms 205 patients received epsilon aminocraproic acid (EACA) and 871 did not. No significant differences between the two groups concerning clinical condition on admission, sex, age, localisation and size of the aneurysms were seen. No cases of rebleeding (RB) were observed within the first 4 days in the EACA treated patients, but within the first 48 hours, which is the optimal period recommended for operation of patients in good clinical condition, this difference of the rates of RB between EACA treated and not treated patients is not significant. A significantly lower rate of RB was observed in the EACA group within the first 2 weeks, but no significant differences in morbidity and mortality were found at the 2-year follow-up examination.
在一项前瞻性连续非随机研究中，纳入了1076例颅内动脉瘤破裂患者，其中205例接受了ε-氨基己酸（EACA）治疗，871例未接受该治疗。两组在入院时的临床状况、性别、年龄、动脉瘤的位置和大小方面均未观察到显著差异。接受EACA治疗的患者在最初4天内未观察到再出血（RB）病例，但在最初48小时内，这是推荐对临床状况良好的患者进行手术的最佳时期，接受EACA治疗和未接受治疗的患者之间的RB发生率差异不显著。在最初2周内，EACA组的RB发生率显著较低，但在2年随访检查中，发病率和死亡率未发现显著差异。
